Vycor's NovaVision Unit Announces the Commercial Release of
NeuroEyeCoach(TM) -- A Novel Saccadic Eye Training Therapy
NeuroEyeCoach(TM) Vision Therapy Is Available Direct to Patients
via the Internet
BOCA RATON, FL--(Marketwired - Jan 23, 2014) - Vycor Medical,
Inc. ("Vycor") (OTCBB: VYCO), a medical device company with a suite
of FDA cleared products, announced today that its wholly-owned
subsidiary, NovaVision has launched the first commercial release of
its new saccadic eye training therapy which will be marketed in the
U.S. as NeuroEyeCoach™. The therapy is now available through
the web site www.NeuroEyeCoach.com.
To carry out normal daily tasks, such as finding an object at
home or on a supermarket shelf, one needs to make effective eye
movements. Unfortunately, normal eye movements are also affected
after brain injury making it difficult to integrate visual
information and adding to the problems of blindness. Training is
needed for patients to learn to make effective use of their eye
movement again. NeuroEyeCoach™ has been specifically developed with
world-renowned professors in the field to increase the efficiency
of eye movement and train the patient to make the most of their
remaining vision.
NeuroEyeCoach™ addresses an enormous worldwide market that
currently is largely not addressed. It is estimated that in the
U.S. alone, there are over 8 million Americans who have suffered a
stroke and there are more than 700,000 new stroke cases occurring
annually. About 30% of patients with acquired brain injury suffer
from visual disorders with stroke being the most frequent
cause.
NeuroEyeCoach™ is an innovative program which evolved from
Professor Zihl's (a NovaVision Scientific Advisor) extensive
research and pioneering of a computer-based saccadic treatment
approach which has been the subject of numerous studies.
NeuroEyeCoach™ distills all of Professor Zihl's clinical findings
into one comprehensive therapeutic product for improving a
patient's ability to scan their environment more efficiently.
NeuroEyeCoach™ is the first commercially available saccadic eye
training therapy offered via the Internet direct to patients at
home. The program is designed to:
- Provide meaningful improvement in visual search performance
resulting in improvements in navigation skills and object
finding.
- Increase the efficiency of a patient's eye movement and
re-train the patient's ability to make most of their remaining
vision
- Be carried out in comfort at home on patient's computer; the
program is intuitive and user friendly and has been designed not to
be overly taxing and can be completed in 2-4 weeks
- Have a real positive impact on activities of daily living.
At www.NeuroEyeCoach.com, information can be found on the
therapy and patients can register and download the program. The
therapy is delivered over the Internet, allowing for the patient to
complete the training in the comfort of their
home. NeuroEyeCoach™ can also be provided as a clinic-based
multi-user device. The device will enable healthcare professionals
to provide the therapy to patients under supervision.
Alternatively, clinics can use the device to enable patients to try
out the therapy while in the clinic. Patients can then be referred
to NovaVision for completion of the NeuroEyeCoach™ therapy at
home.
Commenting on the announcement, David Cantor, President of
Vycor, stated, "We believe today's launch of NeuroEyeCoach™ is a
game changer for Vycor. The therapy addresses a very substantial
and under-served market. NeuroEyeCoach™ has been designed and
developed to meaningfully improve a patient's ability to scan their
environment, resulting in a very positive impact on their ability
to deal with every day living. We believe there are literally
millions of people worldwide who could benefit from this
therapy."
Vycor's wholly-owned NovaVision subsidiary is the worldwide
leader in the field of neurologically-induced vision loss. In
addition to NeuroEyeCoach™, NovaVision markets a non-invasive,
computer-based light stimulation therapy called Vision Restoration
Therapy (VRT™), which is the only medical device aimed at the
restoration of vision for neurologically induced vision loss which
has FDA 510 (K) clearance to be marketed in the U.S.
The NeuroEyeCoach™ therapy is highly complementary to VRT™. The
two therapies address different visual disabilities each of which
results from neurological damage-induced vision loss -- a loss of
visual field as well as difficulty with eye movement, affecting the
ability to integrate visual information. VRT provides partial
restoration of the patient's lost visual field. NeuroEyeCoach™ has
been specifically developed to increase the efficiency of eye
movement and re-train the patients' ability to integrate visual
information between the left and right hand side.
The Company is in parallel actively working on re-engineering
its VRT to also enable it for direct to the patient Internet
delivery and to streamline a number of business processes related
to the delivery and servicing of patients, although the therapy
itself will remain unchanged. Once completed, NovaVision plans to
offer both NeuroEyeCoach™ and VRT alongside each other in one
therapy suite creating the most robust, affordable, Internet-based
visual therapy solution targeted at neurologically induced vision
loss.
NeuroEyeCoach™ is a result of collaboration between Vycor
management, its Chief Scientific Officer Prof. Arash Sahraie,
(Chair in Vision Sciences, College of Life Sciences and Medicine at
the University of Aberdeen) and Josef Zihl and the rest of its
world class NovaVision Scientific Advisory Board.
About Vycor Medical, Inc. Vycor Medical, Inc. ("Vycor") is
dedicated to providing the medical community with innovative and
superior surgical and therapeutic solutions and has a growing
portfolio of FDA-cleared medical solutions that are changing and
improving lives every day. The Company operates two wholly-owned
business units: Vycor Medical and NovaVision, both of which adopt a
minimally or non-invasive approach. Both technologies have
exceptional sales growth potential, address large potential
markets, have the requisite regulatory approvals and are
commercialized and generating revenue.
Vycor Medical's flagship, ViewSite™ Surgical Access Systems
(VBAS) is a suite of clear cylindrical minimally invasive
disposable devices that hold the potential for speedier, safer and
more economical brain surgeries and a quicker patient
discharge. VBAS is designed to optimize neurosurgical site
access, reduce patient risk, accelerate recovery and add tangible
value to the professional medical community. Vycor Medical is ISO
13485:2003 compliant, has FDA 510(K) clearance for VBAS for brain
and spine surgeries and regulatory approvals for brain surgeries in
Australia, Canada, China, Europe, Japan, Korea and Russia. For an
overview of Vycor Medical's VBAS see
http://player.vimeo.com/video/39766887
NovaVision develops and provides science-driven neurostimulation
therapy and other medical technologies that help improve and
partially restore sight in patients with neurological vision
impairments. The company's proprietary Visual Restoration
Therapy® (VRT) platform is clinically supported to improve
lost vision resulting from stroke, traumatic brain injury ("TBI"),
or other acquired brain injuries. VRT is the only FDA 510K cleared
medical device in the U.S. aimed at the restoration of vision for
neurologically induced vision loss and can be prescribed by any
ophthalmologist, optometrist, neurologist or physiatrist. VRT
also has CE Marking for the EU. NovaVision also recently launched
NeuroEyeCoach™, a new Internet-based "direct to the patient"
saccadic eye training program. The Company also provides Neuro-Eye
Therapy (NeET) in the EU, aimed at increasing visual sensitivity
deep within the field defect. For an overview of NovaVision
see: http://player.vimeo.com/video/39765566
For the latest information on the company, including media and
other coverage, and to learn more, please go online at
www.vycormedical.com or www.novavision.com.
Safe Harbor Statement
Information in this document constitute forward-looking
statements or statements which may be deemed or construed to be
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. The words "forecast",
"anticipate", "estimate", "project", "intend", "expect", "should",
"believe", and similar expressions are intended to identify
forward-looking statements. These forward-looking statements
involve, and are subject to known and unknown risks, uncertainties
and other factors which could cause Vycor Medical's actual results,
performance (financial or operating) or achievements to differ from
the future results, performance (financial or operating) or
achievements expressed or implied by such forward-looking
statements. The risks, uncertainties and other factors are more
fully discussed in Vycor Medical's filings with the U.S. Securities
and Exchange Commission. All forward-looking statements
attributable to Vycor Medical herein are expressly qualified in
their entirety by the above-mentioned cautionary statement. Vycor
Medical disclaims any obligation to update forward-looking
statements contained in this estimate, except as may be required by
law.
Brought to you by
www.1800PublicRelations.com
Vycor Medical, Inc. Investor Contacts: The Del Mar Consulting
Group, Inc. Robert B. Prag President 858-794-9500
bprag@delmarconsulting.com Alex Partners, LLC Scott Wilfong
President 425-242-0891 Scott@alexpartnersllc.com Press/Media
Contact: Matthew Bird President MUNCmedia Public Relations +1 (917)
409-8211 matt.bird@muncmedia.com www.muncmedia.com
Vycor Medical (QB) (USOTC:VYCO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Vycor Medical (QB) (USOTC:VYCO)
Historical Stock Chart
From Jul 2023 to Jul 2024